Key Companies in the Pharmacy Market

Why Pharmacy Market Are Expanding?

The Global Pharmacy Market is experiencing sustained, broad-based expansion, growing from USD 1,162.21 billion in 2025 to a projected USD 1,822.58 billion by 2035, at a CAGR of 4.6% over the 2025–2035 forecast period. Market Research Future (MRFR) identifies two primary demand engines driving this trajectory: the accelerating global burden of chronic disease — with the WHO reporting that chronic conditions account for 74% of global deaths — and the rapid digitization of pharmaceutical distribution channels, including telepharmacy and online pharmacy platforms that are extending medication access to underserved populations worldwide.

The alignment of rising healthcare expenditure, aging demographics, and government investment in essential medicine access programs provides durable structural tailwinds for the market across all geographies.

Prescription drugs represent the dominant product segment with a 52% revenue share in 2025, anchored by long-term medication demands for cardiovascular, oncology, and diabetes management. Retail pharmacies lead distribution channels with a 48% share, while the online pharmacy segment is the fastest-growing channel, propelled by the 35% increase in digital health adoption across the Americas as reported by the Pan American Health Organization (PAHO).

Within therapeutic areas, cardiovascular drugs hold the largest revenue share, while oncology is the fastest-growing segment, fueled by rapid innovation in targeted therapies, biologics, and immuno-oncology treatments. Tablets maintain a dominant 58% formulation share, while injectables expand at a faster clip driven by the increasing adoption of biologics and complex specialty pharmaceuticals.

Why These Companies Are Leading the Market?

MRFR identifies four structural factors that define category leadership in the Pharmacy Market: integrated platform breadth spanning distribution, benefits management, and care delivery; scale in specialty and high-complexity pharmaceuticals; proprietary technology investment in digital and AI-enabled pharmacy services; and disciplined M&A strategy to acquire access points and capability gaps. Companies commanding the largest revenue positions in this market combine these factors within vertically integrated models that reduce dependency on any single revenue stream.

Platform breadth defines the position of CVS Health, whose integrated model spans retail pharmacy, pharmacy benefit management (PBM) via Caremark, health insurance through Aetna, and primary care via Oak Street Health and MinuteClinics — creating a closed-loop healthcare ecosystem that drives patient retention and cross-sell. Specialty pharmaceutical scale distinguishes McKesson Corporation and Cencora (formerly AmerisourceBergen), both of which operate industry-leading oncology and ophthalmology specialty networks serving physician offices and hospital systems.

Technology differentiation is exemplified by UnitedHealth Group through Optum Rx, which processed over 1.6 billion prescriptions in FY2024 using AI-powered formulary optimization and biosimilar substitution algorithms. M&A strategy has shaped the competitive positions of Cigna (Evernorth), whose acquisition of Express Scripts created one of the largest PBM operations in the US, processing over 1.5 billion annual scripts.

MRFR assesses that the defining characteristic of a category leader in this market is the ability to manage the full pharmaceutical value chain — from manufacturer contracting through distribution, dispensing, benefits management, and patient adherence programs — within a single commercial relationship. Companies unable to address this full value chain face increasing margin compression as integrated competitors leverage scale to price more aggressively and deliver superior patient outcomes data to employer and government payer clients.

The Rite Aid case — a company that filed for Chapter 11 bankruptcy twice within two years and fully liquidated by September 2025 — illustrates the structural risk facing standalone retail pharmacy operators without integrated benefits management, insurance, or specialty distribution capabilities.

Top 10 Global Pharmacy Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading pharmacy companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

Detailed Company Profiles

1. CVS Health | NYSE: CVS | Woonsocket, Rhode Island, USA

CVS Health operates one of the largest integrated pharmacy and healthcare companies in the United States, combining more than 9,000 retail pharmacy locations, Caremark pharmacy benefit management, Aetna health insurance, and Oak Street Health primary care into a single vertically integrated health services platform. The company's MinuteClinic network provides walk-in health clinic locations embedded within retail pharmacy stores, making CVS Health a comprehensive community-level healthcare access point. CVS Health reported total revenues of USD 372.8 billion in FY2024, up 4.2% year-over-year (per CVS Health Q4/FY2024 earnings release, February 12, 2025).

2. UnitedHealth Group | NYSE: UNH | Minnetonka, Minnesota, USA

UnitedHealth Group participates in the pharmacy market primarily through Optum Rx, the pharmacy care services segment of its Optum health services division, which operates as one of the largest pharmacy benefit managers in the United States. Optum Rx manages prescription drug benefits for employer clients, health plan members, and government programs, leveraging AI-driven formulary optimization to improve drug cost efficiency and patient adherence outcomes. UnitedHealth Group reported total revenues of USD 400.3 billion in FY2024, up 7.7% year-over-year (per UnitedHealth Group FY2024 results, January 16, 2025). In August 2025, UnitedHealth closed its long-delayed USD 3.3 billion acquisition of home health and hospice provider Amedisys, following a two-year regulatory battle that included a DOJ antitrust lawsuit and a settlement requiring divestiture of 164 facilities.

3. McKesson Corporation | NYSE: MCK | Irving, Texas, USA

McKesson Corporation is a leading pharmaceutical distribution company in North America, supplying branded, generic, specialty, and biosimilar drugs to pharmacies, health systems, physician offices, and surgery centers across the United States and Canada. McKesson's US Pharmaceutical segment distributes a substantial share of prescription drugs consumed in the United States, serving tens of thousands of pharmacy locations including major retail chains, independent pharmacies, and community health centers.

The company's oncology platform, The US Oncology Network, is among the largest community oncology networks in the US. McKesson reported consolidated revenues of USD 359.1 billion for fiscal year 2025 (fiscal year ended March 31, 2025), an increase of 16% year-over-year (per McKesson Q4/FY2025 earnings release, May 8, 2025). Note: The original document stated USD 308.9B; the validated FY2025 figure is USD 359.1B. In April 2025, McKesson completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, expanding its ophthalmology and retina specialty management services capabilities.

4. Cencora (AmerisourceBergen) | NYSE: COR | Conshohocken, Pennsylvania, USA

Cencora, formerly AmerisourceBergen, is a leading pharmaceutical distribution company globally, supplying drugs, specialty biologics, and healthcare products to retail pharmacies, health systems, physician offices, and animal health customers across more than 50 countries. The company's World Courier business provides global specialty logistics and temperature-controlled pharmaceutical supply chain services to clinical trial sponsors and specialty drug manufacturers.

Cencora reported revenue of USD 294.0 billion for fiscal year 2024, a 12.1% increase year-over-year (per Cencora Q4/FY2024 earnings release, November 2024). In November 2024, Cencora announced a definitive agreement to acquire Retina Consultants of America (RCA) for approximately USD 4.6 billion in cash (with a closing cash outlay of USD 4.4 billion), plus up to USD 500 million in contingent consideration, expanding its specialty ophthalmology management services capabilities; the acquisition closed in 2025.

5. Cardinal Health | NYSE: CAH | Dublin, Ohio, USA

Cardinal Health is a major US pharmaceutical distributor and healthcare services company, supplying branded and generic pharmaceuticals, specialty drugs, and nuclear pharmacy products to hospitals and pharmacy locations across the United States. The company's pharmaceutical and specialty solutions segment distributes drugs and medical products to retail pharmacies, health systems, nuclear pharmacies, and physician offices, while its specialty pharmaceutical distribution division serves manufacturer services and oncology drug distribution through a network of nuclear pharmacies and specialty distribution centers.

Cardinal Health reported total revenue of USD 226.8 billion for fiscal year 2024, up approximately 11% year-over-year (per Cardinal Health Q4/FY2024 earnings release, August 14, 2024). Cardinal Health has been advancing the planned separation of its Medical-Surgical Solutions (GMPD) segment to refocus capital deployment on pharmaceutical and specialty distribution.

6. Walgreens Boots Alliance | Deerfield, Illinois, USA

Walgreens Boots Alliance operates the Walgreens retail pharmacy chain in the United States alongside the leading UK pharmacy chain Boots, serving communities across 25+ countries. The company's US Pharmacy segment fills hundreds of millions of prescriptions annually and provides clinical pharmacy services including immunizations and medication therapy management through its healthcare clinics.

Walgreens Boots Alliance reported fiscal year 2024 sales of USD 147.658 billion, up 6.2% year-over-year (per Walgreens Boots Alliance FY2024 Form 10-K, fiscal year ended August 31, 2024). The company has since been taken private by Sycamore Partners, with the take-private transaction completing in 2025, and announced a multi-year footprint optimization program targeting approximately 1,200 store closures.

7. Cigna (Evernorth) | NYSE: CI | Bloomfield, Connecticut, USA

Cigna's pharmacy market participation is centered on Evernorth Health Services, its health services segment encompassing Express Scripts, Accredo specialty pharmacy, and CuraScript specialty distribution. Express Scripts manages pharmacy benefits for tens of millions of patients across employer, government, and health plan clients in the United States, processing over 1.5 billion prescriptions annually.

Accredo specialty pharmacy delivers complex biologic medications for conditions including oncology, multiple sclerosis, hemophilia, and inflammatory diseases. The Cigna Group reported total revenues of USD 247.1 billion for FY2024, an increase of 27% year-over-year, primarily driven by growth in Evernorth Health Services (per The Cigna Group Q4/FY2024 earnings release, January 30, 2025).

8. Rite Aid | Philadelphia, Pennsylvania, USA (Operations Ceased September 2025)

Rite Aid Corporation, once the third-largest US retail pharmacy chain by store count, no longer operates as an ongoing business. The company first filed for Chapter 11 bankruptcy in October 2023, completed the court-approved sale of its Elixir pharmacy benefit management subsidiary to MedImpact Healthcare Systems for approximately USD 576.5 million (closing February 2024), and emerged from its first bankruptcy as a private company on September 3, 2024, with roughly USD 2 billion in debt eliminated.

However, persistent financial pressure led Rite Aid to file a SECOND Chapter 11 bankruptcy in May 2025, at which point the company pursued a full wind-down and sale of its prescription files and assets to chains including CVS, Walgreens, Albertsons, and Kroger. Rite Aid's last 89 remaining stores closed by September 30, 2025, ending the company's 63-year operating history. Note: The original document described Rite Aid as an active retail pharmacy operator with an in-house Elixir PBM business across 17 states; both claims are now outdated — Elixir was divested in 2024 and Rite Aid itself has fully ceased operations.

9. Teva Pharmaceutical Industries | NYSE: TEVA | Tel Aviv, Israel

Teva Pharmaceutical Industries is one of the world's largest generic drug companies by volume, producing thousands of generic medicine products across virtually all therapeutic areas and distributing to 60+ countries globally. The company operates a dual-segment model — generic pharmaceuticals providing the volume and margin base, and a growing specialty pharmaceutical segment anchored by Austedo (deutetrabenazine) for tardive dyskinesia and Huntington's disease and AJOVY (fremanezumab) for migraine prevention.

Teva reported revenues of USD 16.544 billion for FY2024, an increase of 4% in US dollar terms (6% in local currency terms) compared to 2023 (per Teva Q4/FY2024 earnings release, January 29, 2025). On December 31, 2024, Teva classified its API business as held for sale.

10. Sinopharm Group | HKEX: 1099 | Beijing, China

Sinopharm Group is one of China's largest pharmaceutical distribution and healthcare services conglomerates, operating a nationwide pharmaceutical logistics and distribution network that serves hospitals, pharmacies, and healthcare institutions across mainland China. The company's operations span pharmaceutical wholesale distribution, retail pharmacy chain management, medical device distribution, and pharmaceutical manufacturing through a multi-layered network of distribution centers and retail pharmacy outlets under the Guoda Drugstore brand.

Sinopharm reported revenue of CNY 584.5 billion (approximately USD 80.1 billion) for FY2024, a decline of 2.0% year-over-year, with net income also declining 22% (per Sinopharm Group FY2024 results). Note: The original document stated CNY 605.8 billion; the validated FY2024 figure is CNY 584.5 billion, reflecting a revenue contraction rather than growth.

M&A Activity Tracker (2022–2026)

The Pharmacy Market has experienced significant consolidation as integrated health services operators pursue inorganic growth to extend capabilities into specialty pharmaceuticals, physician-administered drug dispensing, and digital healthcare access, while distributors acquire specialty networks to capture high-margin biologics volume ahead of anticipated biosimilar growth cycles. Market Research Future tracks the following verified transactions directly relevant to the pharmacy market.

Key Trend. MRFR analysis identifies specialty pharmaceutical network acquisition and vertical integration of PBM with care delivery as the dominant M&A themes in the pharmacy market, with acquirers prioritizing physician-dispensing networks, specialty oncology and ophthalmology assets, and home-based care capabilities that capture high-margin prescription volume outside traditional retail dispensing channels. Regulatory scrutiny has also become a defining feature of large pharmacy-adjacent M&A, as illustrated by the two-year DOJ review of the UnitedHealth/Amedisys transaction.

R&D Investment & Innovation Signals

R&D investment across the Pharmacy Market has increased materially in 2025–2026 as pharmacy operators, distributors, and pharmaceutical manufacturers invest in AI-enabled pharmacy operations, biosimilar pipeline development, and advanced therapy dispensing infrastructure, addressing the primary commercial barrier to scaling high-complexity, high-value drug therapies. Market Research Future tracks the following 2025–2026 R&D and technology programs from official company sources:

• CVS Health has expanded AI-powered clinical decision support tools within Caremark, deploying machine learning algorithms to identify high-risk patients for proactive medication therapy management outreach.

• UnitedHealth Group (Optum Rx) has invested in generative AI-powered medication adherence programs, automating personalized patient communication campaigns across SMS, app, and voice channels to improve adherence rates for cardiometabolic chronic disease medications across its large PBM membership base.

• McKesson Corporation has advanced digital infrastructure investment across The US Oncology Network, deploying a unified electronic health record (EHR) and oncology pharmacy management platform across its community oncology practices to standardize clinical data capture.

• Cencora (AmerisourceBergen) has developed its World Courier clinical trial logistics digital platform, deploying IoT-enabled cold-chain monitoring and real-time temperature excursion alerts across clinical trial supply chains globally to reduce drug wastage in high-value biologic clinical studies.

• Cigna (Evernorth) has launched an AI-driven specialty drug prior authorization platform within Express Scripts aimed at reducing prior authorization decision time for specialty oncology and immunology drug requests, improving patient time-to-therapy.

• Teva Pharmaceutical Industries has expanded its biosimilar formulation development capabilities, filing regulatory applications for new biosimilar products across the US and EU, advancing a biosimilar pipeline spanning oncology supportive care, inflammatory disease, and ophthalmology.

Industry Signal. MRFR identifies the convergence of AI-enabled pharmacy operations — spanning formulary optimization, medication adherence automation, and real-time clinical decision support — with the accelerating specialty pharmaceutical and biosimilar market as the overarching innovation direction reshaping competitive differentiation in the Pharmacy Market, with operators that successfully integrate AI across the full prescription lifecycle from prescribing through dispensing and adherence positioned to define the next generation pharmacy services standard. The collapse of Rite Aid as a standalone retail pharmacy operator also signals that scale, integration, and specialty capability — not store count alone — increasingly determine which pharmacy operators remain viable.